SCHEMBL1650677

SCHEMBL1650677

CC(C)C[C@H](CC(N)=O)C(N)=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.43
SLC1A2 P43004 1/20 0.43
SLC7A5 Q01650 1/20 0.39
CACNA2D1 P54289 2/20 0.39
CACNB3 P54284 1/20 0.39
CACNA1C Q13936 1/20 0.39
PGR P06401 1/20 0.39
ADRA1A P35348 1/20 0.39
HTR2B P41595 1/20 0.39
CACNA2D2 Q9NY47 1/20 0.39
CPA1 P15085 1/20 0.36
ANPEP P15144 2/20 0.36
LAP3 P28838 1/20 0.36
IL1RN P18510 2/20 0.36
ERAP2 Q6P179 2/20 0.36
ERAP1 Q9NZ08 2/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
MME P08473 2/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL743997 1.00 SLC1A3 (0.43) SLC1A3SLC1A2SLC7A5CACNA2D1CACNB3
SCHEMBL28601320 0.87 CA1 (0.37) CA1CA2ALDH1A1TDP1
SCHEMBL276673 0.85 SLC1A3 (0.50) SLC1A3SLC1A2SLC7A5CACNA2D1CACNB3
SCHEMBL28893916 0.84 CA1 (0.34) CA1CA2ALDH1A1
SCHEMBL7094095 0.84 CACNA2D1 (0.52) SLC1A3SLC1A2SLC7A5CACNA2D1CACNB3
SCHEMBL10000212 0.84 CACNA2D1 (0.52) SLC1A3SLC1A2SLC7A5CACNA2D1CACNB3
SCHEMBL7094101 0.84 SLC1A3 (0.57) SLC1A3SLC1A2SLC7A5CACNA2D1CACNB3
SCHEMBL20548024 0.84 SLC1A3 (0.57) SLC1A3SLC1A2SLC7A5CACNA2D1CACNB3
SCHEMBL16141043 0.82 SLC1A3 (0.41) SLC1A3SLC1A2SLC7A5CACNA2D1CACNB3
SCHEMBL6690561 0.80 SLC1A3 (0.39) SLC1A3SLC1A2SLC7A5CACNA2D1CACNB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1005448-A2 NOVEL INHIBITORS OF AGGRECANASE AND MATRIX METALLOPROTEINASES FOR THE TREATMENT OF ARTHRITIS Du Pont Pharmaceuticals Company (US) 2000-06-07 EP claimed
WO-1999009000-A2 NOVEL INHIBITORS OF AGGRECANASE AND MATRIX METALLOPROTEINASES FOR THE TREATMENT OF ARTHRITIS DU PONT PHARMACEUTICALS COMPANY (US) 1999-02-25 WO claimed
US-7927613-B2 Pharmaceutical co-crystal compositions UNIVERSITY OF SOUTH FLORIDA (US) 2011-04-19 US disclosed
EP-1796602-A2 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE Angiotech Pharmaceuticals (US), Inc. (US) 2007-06-20 EP disclosed
WO-2006034128-A2 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE ANGIOTECH BIOMATERIALS CORPORATION (US) 2006-03-30 WO disclosed
EP-1047450-A1 ACE INHIBITOR-MMP INHIBITOR COMBINATIONS WARNER-LAMBERT COMPANY (US) 2000-11-02 EP disclosed
EP-1005448-A2 NOVEL INHIBITORS OF AGGRECANASE AND MATRIX METALLOPROTEINASES FOR THE TREATMENT OF ARTHRITIS Du Pont Pharmaceuticals Company (US) 2000-06-07 EP disclosed
EP-0946166-A1 USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING WARNER-LAMBERT COMPANY (US) 1999-10-06 EP disclosed
WO-1999032150-A1 ACE INHIBITOR-MMP INHIBITOR COMBINATIONS WARNER-LAMBERT COMPANY (US) 1999-07-01 WO disclosed
WO-1999009000-A2 NOVEL INHIBITORS OF AGGRECANASE AND MATRIX METALLOPROTEINASES FOR THE TREATMENT OF ARTHRITIS DU PONT PHARMACEUTICALS COMPANY (US) 1999-02-25 WO disclosed
WO-1998026773-A1 USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING WARNER-LAMBERT COMPANY (US) 1998-06-25 WO disclosed